New hope for young AML patients: drug cocktail targets resistant cancer

NCT ID NCT05317403

Recruiting now Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether adding the drug venetoclax to a standard chemotherapy regimen can help children and young adults whose acute myeloid leukemia (AML) has come back or not responded to treatment. About 40 participants will receive different doses of venetoclax along with other drugs to see what dose is safe and whether it improves response. The goal is to find a better way to control this aggressive cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (a targeted cancer drug) combined with azacitidine, vorinostat, and cytarabine (chemotherapy)
What this could lead to: If successful, this could lead to a more effective treatment option for children and young adults with hard-to-treat AML that has returned or not responded to standard therapy.
What could go wrong: This is a very early phase 1 trial with only 40 participants, focused on finding a safe dose. It is not yet known if the combination works better than existing treatments, and there are risks of serious side effects from the drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia therapy-related myeloid neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA, IN RELAPSE

Contacts and locations

Locations

Children's Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.